This is a StreetInsider.com Premium Only Page

Evoke Pharma (EVOK) –

Apr 17, 2024 08:30 AM Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Apr 10, 2024 03:37 PM Form ARS Evoke Pharma Inc For: Dec 31

Apr 10, 2024 03:36 PM Form DEFA14A Evoke Pharma Inc

Apr 10, 2024 03:35 PM Form DEF 14A Evoke Pharma Inc For: Apr 10

Mar 29, 2024 04:04 PM Form PRE 14A Evoke Pharma Inc For: Mar 29

Mar 25, 2024 04:57 PM Form 424B3 Evoke Pharma Inc

Mar 25, 2024 04:56 PM Form 8-K Evoke Pharma Inc For: Mar 25

Mar 21, 2024 04:16 PM Evoke Pharma (EVOK) Appoints Matthew J. D’Onofrio as CEO

Mar 21, 2024 04:16 PM Form 8-K Evoke Pharma Inc For: Mar 20

Mar 21, 2024 04:15 PM Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer

Mar 18, 2024 05:02 PM Form 8-K Evoke Pharma Inc For: Mar 18

Mar 15, 2024 06:11 AM Form POS EX Evoke Pharma Inc

Mar 15, 2024 06:09 AM Form 424B3 Evoke Pharma Inc

Mar 14, 2024 04:45 PM Evoke Pharma (EVOK) Misses Q4 EPS by 9c

Mar 14, 2024 04:05 PM Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 14, 2024 04:01 PM Form 10-K Evoke Pharma Inc For: Dec 31

Mar 14, 2024 04:00 PM Form 8-K Evoke Pharma Inc For: Mar 14

Mar 13, 2024 01:37 PM Evoke Pharma (EVOK): Laurence W. Lytton Reports 9.99% Passive Stake

Mar 13, 2024 01:33 PM Form SC 13G Evoke Pharma Inc Filed by: LYTTON LAURENCE W

Mar 11, 2024 06:39 PM Form SC 13G Evoke Pharma Inc Filed by: Bleichroeder LP

Mar 7, 2024 04:10 PM Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

Feb 23, 2024 04:21 PM Evoke Pharma (EVOK) Receives Nasdaq Non-compliance Notice

Feb 23, 2024 04:17 PM Form 8-K Evoke Pharma Inc For: Feb 21

Feb 20, 2024 04:39 PM Form SC 13G Evoke Pharma Inc Filed by: Altium Capital Management LP

Feb 14, 2024 09:00 AM Form 8-K Evoke Pharma Inc For: Feb 13

Feb 14, 2024 07:30 AM Evoke Pharma Announces Closing of $7.5 Million Public Offering

Feb 13, 2024 06:34 AM Form SC 13G Evoke Pharma Inc Filed by: HIRSCHMAN ORIN

Feb 9, 2024 05:16 PM Form 8-K Evoke Pharma Inc For: Feb 08

Feb 9, 2024 05:15 PM Form 424B4 Evoke Pharma Inc

Feb 9, 2024 07:31 AM Evoke Pharma (EVOK) Prices Underwritten Public Offering of up to $30 Million

Feb 9, 2024 07:30 AM Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Feb 9, 2024 06:03 AM Form EFFECT Evoke Pharma Inc

Feb 8, 2024 06:53 AM Evoke Pharma (EVOK) Announces 10M Unit Offering

Feb 8, 2024 06:51 AM Form S-1/A Evoke Pharma Inc

Jan 11, 2024 06:04 AM Evoke Pharma (EVOK) Announces 8.33M Unit Offering

Jan 11, 2024 06:02 AM Form S-1/A Evoke Pharma Inc

Jan 4, 2024 04:36 PM Evoke Pharma (EVOK) Announces 14.56M Share and Warrant Offering

Jan 4, 2024 04:31 PM Form S-1/A Evoke Pharma Inc

Dec 19, 2023 08:33 AM Evoke Pharma (EVOK) Announces Share and Warrant Offering

Dec 19, 2023 08:31 AM Form S-1/A Evoke Pharma Inc

Dec 15, 2023 04:31 PM Form S-1/A Evoke Pharma Inc

Nov 29, 2023 09:00 AM Form 8-K Evoke Pharma Inc For: Nov 27

Nov 27, 2023 04:30 PM Form 8-K Evoke Pharma Inc For: Nov 27

Nov 27, 2023 08:30 AM Evoke Pharma (EVOK) Announces FDA Orange Book Listing of New GIMOTI Patent

Nov 27, 2023 08:30 AM Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

Nov 22, 2023 04:15 PM Form 8-K Evoke Pharma Inc For: Nov 21

Nov 14, 2023 08:30 AM United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Nov 9, 2023 04:32 PM Form S-1 Evoke Pharma Inc

Nov 9, 2023 09:06 AM Evoke Pharma (EVOK) Tops Q3 EPS by 11c

Nov 9, 2023 09:01 AM Form 10-Q Evoke Pharma Inc For: Sep 30